文献速递肿瘤 PET/CT

[18F]DCFPyL PET/MRI与多参数MRI检测临床显著性前列腺癌的前瞻性分析:与根治性前列腺切除标本组织病理学的比较,ProStaPET研究

Prospective analysis of clinically significant prostate cancer detection with [18F]DCFPyL PET/MRI compared to multiparametric MRI: a comparison with the histopathology in the radical prostatectomy specimen, the ProStaPET study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-11-02

本研究前瞻性纳入30例中高危前列腺癌患者,在机器人辅助根治性前列腺切除术前分别行[18F]DCFPyL PET/MRI与多参数MRI,以术后病理为参考标准评估两者对临床显著性前列腺癌(GG≥2)的定位诊断效能及活检建议。结果显示两种影像在患者水平对最高GG病灶的检出率均为90.0%,但[18F]DCFPyL PET/MRI在分段水平并未优于多参数MRI。

要点

  • 30例中高危前列腺癌患者术前均行[18F]DCFPyL PET/MRI与多参数MRI检查。
  • 两种影像的活检建议在27/30例(90.0%)中包含了最高GG病灶。
  • 分段水平[18F]DCFPyL PET/MRI的AUC为0.70,多参数MRI为0.75。

核心结论

  • [18F]DCFPyL PET/MRI与多参数MRI均仅能部分检测分段水平的临床显著性前列腺癌。
  • 在患者水平,两种影像的活检建议与根治性前列腺切除标本组织病理学比较,对最高GG病灶的检出率均为90.0%。
  • 尽管[18F]DCFPyL PET/MRI能充分检测临床显著性前列腺癌,但并未优于多参数MRI。

研究设计与样本

  • 前瞻性纳入30例中高危前列腺癌患者,在机器人辅助根治性前列腺切除术前分别行[18F]DCFPyL PET/MRI与多参数MRI。
  • 由2名核医学医师和2名放射科医师分别评估[18F]DCFPyL PET/MRI和多参数MRI的肿瘤定位,并使用14分段前列腺模型给出前列腺活检建议(2个分段)。
  • 由泌尿病理学家使用同一模型评估根治性前列腺切除标本中的临床显著性前列腺癌,定义为任何Grade Group(GG)≥2的前列腺癌。
  • 将基于影像的活检建议与根治性前列腺切除标本的最终组织学进行完全一致分析,并额外进行近似一致分析以接近临床实际。

主要发现

  • 病理检查后,420个分段中有142个(33.8%)包含临床显著性前列腺癌。
  • 基于[18F]DCFPyL PET/MRI的活检建议在27/30例患者(90.0%)中包含最高GG前列腺癌分段,基于多参数MRI的活检建议同样为27/30例(90.0%)。
  • 分段水平完全一致检测临床显著性前列腺癌时,[18F]DCFPyL PET/MRI的AUC为0.70,灵敏度50.0%,特异度89.9%,阳性预测值71.7%,阴性预测值77.9%。
  • 分段水平完全一致检测临床显著性前列腺癌时,多参数MRI的AUC为0.75,灵敏度54.2%,特异度94.2%,阳性预测值82.8%,阴性预测值80.1%。

关键数值与推荐

  • 临床显著性前列腺癌定义为任何Grade Group(GG)≥2的前列腺癌。
  • 影像评估采用14分段前列腺模型,活检建议为2个分段。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Multiparametric magnetic resonance imaging (mpMRI) is a well-established imaging method for localizing primary prostate cancer (PCa) and for guiding targeted prostate biopsies. [18F]DCFPyL positron emission tomography combined with MRI (PSMA-PET/MRI) might be of additional value to localize primary PCa. The aim of this study was to assess the diagnostic performance of [18F]DCFPyL-PET/MRI vs. mpMRI in tumour localization based on histopathology after robot-assisted radical-prostatectomy (RARP), also assessing biopsy advice for potential image-guided prostate biopsies. METHODS: Thirty prospectively included patients with intermediate to high-risk PCa underwent [18F]DCFPyL-PET/MRI and mpMRI prior to RARP. Two nuclear medicine physicians and two radiologists assessed tumour localization on [18F]DCFPyL-PET/MRI and on mpMRI respectively, and gave a prostate biopsy advice (2 segments) using a 14-segment model of the prostate. The uro-pathologist evaluated the RARP specimen for clinically significant PCa (csPCa) using the same model. csPCa was defined as any PCa with Grade Group (GG) ≥ 2. The biopsy advice based on imaging was correlated with the final histology in the RARP specimen for a total-agreement analysis. An additional near-agreement correlation was performed to approximate clinical reality. RESULTS: Overall, 142 of 420 (33.8%) segments contained csPCa after pathologic examination. The segments recommended for targeted biopsy contained the highest GG PCa segment in 27/30 patients (90.0%) both for [18F]DCFPyL-PET/MRI and mpMRI. Areas under the receiver operating characteristics curves (AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for the total-agreement detection of csPCa per segment using [18F]DCFPyL-PET/MRI were 0.70, 50.0%, 89.9%, 71.7%, and 77.9%, respectively. These results were 0.75, 54.2%, 94.2%, 82.8%, and 80.1%, respectively, for mpMRI only. CONCLUSION: Both [18F]DCFPyL-PET/MRI and mpMRI were only partly able to detect csPCa on a per-segment basis. An accurate detection (90.0%) of the highest GG lesion at patient-level was observed when comparing both [18F]DCFPyL-PET/MRI and mpMRI biopsy advice with the histopathology in the RARP specimen. So, despite the finding that [18F]DCFPyL-PET/MRI adequately detects csPCa, it does not outperform mpMRI.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Bodar YJL, Zwezerijnen BGJC, van der Voorn PJ, et al. Prospective analysis of clinically significant prostate cancer detection with [18F]DCFPyL PET/MRI compared to multiparametric MRI: a comparison with the histopathology in the radical prostatectomy specimen, the ProStaPET study. Eur J Nucl Med Mol Imaging. 2021. PMID: 34725727. doi:10.1007/s00259-021-05604-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。